

1 **Title**

2 **Initial experience in Mexico with convalescent plasma in COVID-19 patients with**
3 **severe respiratory failure, a retrospective case series**

4

5 **Authors:**

6 Michel F. Martinez-Resendez¹, Fernando Castilleja-Leal¹, Alejandro Torres-Quintanilla¹,
7 Augusto Rojas-Martinez¹, Gerardo Garcia-Rivas¹, Rocio Ortiz-Lopez¹, Victor Trevino¹,
8 Reynaldo Lara-Medrano¹, Hiram Villanueva-Lozano¹, Teresa Ramirez-Elizondo¹, Victor
9 M. Sanchez-Nava¹, Francisco Moreno-Hoyos¹, Alfonso Martinez-Thomae¹, Martin
10 Hernández-Torre¹, Carlos Diaz-Olachea¹, Servando Cardona-Huerta¹, Sylvia de la Rosa-
11 Pacheco¹, Carlos Diaz-Garza¹, Paola Reynoso-Lobo¹, Alma R. Marroquin-Escamilla¹,
12 Jessica G. Herrera-Gamboa¹, Fatima M. Alvarado-Monroy¹, Claudia D. Aguayo-Millan¹,
13 Francisco F. Villegas-Macedo¹, Jesus Efrain Flores-Osorio¹, Daniel Davila-Gonzalez¹,
14 María Eugenia Diaz-Sanchez¹, Guillermo Torre-Amione^{1,*}.

15 ¹ Tecnológico de Monterrey, Escuela de Medicina y Ciencias de la Salud,
16 Monterrey, Mexico.

17 ***Corresponding author: Guillermo Torre-Amione.** Tecnológico de Monterrey, Escuela
18 de Medicina y Ciencias de la Salud, Monterrey, Mexico, gtorre@tecsalud.mx

19 **Abstract**

20 **Introduction:** Hospital mortality due to COVID-19 in Mexico is high (32%) and as of
21 today, effective treatment options are limited. More effective treatments that shorten
22 hospital stay and reduce mortality are needed. Initial reports for the use of convalescent
23 plasma (CP) therapy for COVID-19 appear promising. We describe a case series of eight
24 patients with impending respiratory failure, who underwent CP therapy.

25 **Methods:** Six male and two female (ages 31 to 79) patients that were admitted to the
26 intensive-care unit for severe COVID-19 were transfused with two doses of CP (250 mL
27 per dose, anti-SARS-CoV-2 IgG titers > 1:100). Donors were six SARS-CoV-2 infected
28 males who remained asymptomatic for > 7 days and were negative for two nasopharyngeal
29 RT-PCR tests. Clinical characteristics, inflammatory and cellular injury markers, chest X-
30 ray findings and viral loads were analyzed before and after CP administration. Viral load
31 association to disease severity was further analyzed on a separate cohort of asymptomatic
32 vs hospitalized patients with COVID-19.

33 **Results:** Eight patients with respiratory failure were successfully discharged with a median
34 length of stay of 22.5 (IQR 18.25-29.00). After CP therapy, we observed a reduction of C-
35 reactive protein (CRP) (median, 22.80 mg/dL vs. 1.63 mg/dL), and of procalcitonin
36 (median, 0.27 ng/mL vs. 0.13 ng/mL). High-Sensitivity Cardiac Troponin I (hs-cTnI),
37 Brain Natriuretic Peptide (BNP) and Lactate Dehydrogenase (LDH) were lower, and a mild
38 reduction of pulmonary infiltrates by chest X-ray was observed. Lastly, a reduction of viral
39 load was after CP therapy was found. (log, median [IQR], 1.2 [0.70-2.20] vs. 0.25 [0.00-
40 1.78]). We observed no adverse effects.

41 **Conclusions:** CP could potentially be an effective therapeutic option for patients with
42 severe COVID-19. Clinical benefit needs to be studied further through randomized
43 controlled trials.

44

45 **Keywords:** COVID-19, SARS-CoV-2, convalescent plasma, Mexico, case series

46 **Introduction**

47 As the COVID-19 pandemic has progressed, it has shifted epicenter into the Americas. As
48 of June 9, 4 of the 10 nations with the highest number of new cases are Latin American
49 countries: Brazil, Peru, Chile and Mexico (1). Complicating things further, Mexico has seen
50 an increasing hospital mortality, which stands now at 32% (2). Hospital saturation must be
51 an involved factor explaining said high mortality, as Mexico reports the lowest number of
52 hospital beds per 1,000 habitants among the OECD member countries, as per the latest data
53 (3). Certainly, therapies that reduce mortality and shorten hospital stay are needed globally.
54 As there are few therapeutic options, such as antivirals and monoclonal antibodies, and
55 their potential efficacy is still being determined, convalescent plasma (CP) could represent
56 a lower cost alternative (4). This last property could be particularly helpful for developing
57 countries, if CP is proven to be effective.

58 As CP has been used for more than a century for the treatment of different
59 infectious diseases, especially during epidemics or pandemics such as SARS, influenza or
60 Ebola virus, there is vast experience with this safe therapeutic alternative. Nonetheless, the
61 mechanisms of action may vary for every virus for which it is used, and are still being
62 revisited (5). CP has been successfully used in the treatment of SARS and MERS.
63 Moreover, recent independent studies of CP therapy in patients with COVID-19 provide
64 evidence for its use (6–8). In this paper we describe our initial experience with the use of
65 CP in a case series of patients with COVID-19 with impending respiratory failure.

66

67 **Materials and methods**

68 **Patients**

69 Eight critically ill patients with COVID-19 that were admitted to the COVID-19 Unit at
70 Hospital San José TecSalud in Monterrey, Mexico, from March 10 to May 21, 2020,
71 received CP therapy. All patients had impending respiratory failure associated with
72 COVID-19 and were confirmed by RT-PCR testing before received treatment with CP.
73 ABO and Rh blood types of the patients were determined for potential compatibility with
74 the CP donor, and each subject received two transfusions of 250 mL of CP separated by 24
75 hours. Plasma was infused at 20 mL/min and monitored for 15 minutes after the infusion
76 and no premedication was used. All patients were previously initiated on local established
77 and protocolized therapy including antiviral agents, moreover the patients received
78 supportive care such as antibiotic treatment, antipyretics, analgesics, fluids and nutrition.
79 This study was approved by the Clinical Research Ethics Committee of the School of
80 Medicine at Tecnológico de Monterrey (P000353-COVID-19 TecSalud-CEIC-CR001).
81 Written informed consent was obtained from all patients. All patients received CP
82 treatment under compassionate use due to impending respiratory failure after case review
83 by the hospital bioethics committee.

84

85 **Donors**

86 We obtained CP from 6 male donors who were between the ages of 22 and 57 years. The
87 donors had recovered from SARS-CoV-2 infection with at least 7 days without any
88 symptoms and 2 negative RT-PCR tests. They were invited to donate their plasma after

89 written informed consent was obtained. In addition, the donors were screened to rule out
90 hepatitis B virus, hepatitis C virus, Epstein Barr virus, HIV, *Brucella abortus*,
91 *Trypanosoma cruzi* and syphilis infection at the time of blood donation. Donors showed
92 anti-SARS-CoV-2 IgG antibody titers higher than 1:100 as determined by ELISA. Written
93 informed consent was obtained and ABO-compatible plasma samples were obtained by
94 apheresis. Depending on bodyweight, 600-800 mL were collected and divided into 250 mL
95 aliquots. A first dose of CP was transfused to recipients at baseline and a second dose 24
96 hours afterwards.

97

98 **Clinical information**

99 Data from patients was obtained from medical records. Retrieved data included:
100 demographics, symptoms, days from symptom onset to admission, length of stay,
101 pharmacologic therapy, type and duration of ventilator support, vital signs (temperature,
102 heart rate, respiratory rate, SaO₂/FiO₂, and blood pressure), severity scores [Sequential
103 Organ Failure Assessment (SOFA), the quick Sequential Organ Failure Assessment
104 (qSOFA), the Pneumonia Severity Index (PSI), the Confusion, blood Urea nitrogen,
105 Respiratory rate, Blood pressure, age 65 score (CURB-65)], laboratory data [complete
106 blood count, blood chemistry, liver function testing, cultures, SARS-CoV-2 transcript
107 copies, inflammatory markers like C-reactive protein (CRP), procalcitonin, troponin, brain
108 natriuretic peptide (BNP), lactate dehydrogenase (LDH), D-dimer, ferritin and interleukin-6
109 (IL-6)], chest X-Ray or CT-scan findings, and clinical events and outcomes (ARDS,
110 bacterial pneumonia, multiple organ dysfunction syndrome and death). Inflammation
111 markers were taken at admission, before each dose of CP and at 48 hours follow-up.

112 **Patient cohort for viral load control group**

113 Discarded samples from clinical laboratory were obtained to determine viral load in a group
114 of asymptomatic outpatients (n=23) as well as in hospitalized COVID-19 patients. (n=21).

115

116 **Chest X-ray pulmonary infiltrates severity scoring**

117 All patients were evaluated for pulmonary infiltrates severity on chest X-ray as previously
118 reported (9). Briefly, each lung is assigned a score of 0-4 depending on the extent of
119 consolidation or ground-glass opacities as follows: 0 = no involvement; 1 = <25%; 2 = 25-
120 50%; 3 = 50-75%; 4 = >75% involvement. The final score corresponds to the sum of the
121 scores for each lung.

122

123 **RT-PCR Test**

124 We used the Applied Biosystems™ TaqMan™ 2019-nCoV Assay Kit v1 (Cat. No.
125 A47532) for the qualitative detection and characterization of 2019-nCoV RNA. The kit
126 includes three PCR assays that target viral genes, and one positive control assay that targets
127 the Human RNase P RPPH1 gene. The reactions were performed according to
128 manufacturer instructions. Briefly, the 25uL reactions for each 2019-nCoV assay include
129 Master Mix 6.25uL, 2019-nCoV assay primers and probes per gene 1.25 uL, RNase P
130 1.25uL, RT-PCR grade water 11.25uL, and testing sample 5uL. The testing sample could
131 be a biological specimen from a patient, positive control (A47533), or water as non-
132 template control. The cycling conditions were 2 min @ 25°C, 10 min @ 50°C, 2 min @
133 95°C, and 40-45 cycles of 3 sec @ 95°C and 30 sec @ 60°C. This PCR program was run in

134 a QuantStudio 5 Real-Time PCR system (ThermoFisher). Automatic threshold detection
135 was used as instructed. A sample is positive if at least two of the three COVID-19 genes
136 amplifications were detected above threshold before cycle 38. A negative result is given if
137 no amplification of the three COVID-19 genes was observed. An invalid result is given if
138 any of the three amplifications of RNase P was not observed before cycle 38. If otherwise,
139 an indeterminate result is given. If an indeterminate result is observed, the set of reactions
140 for the sample is repeated and the result is reported. To estimate the viral load, we used a
141 dilution series of the positive control (A47533) included in each PCR plate and used the
142 regression curve to estimate the minimum and maximum viral load from the curves of each
143 of the three viral genes. The regression was estimated automatically by the Design &
144 Analysis Software Release Version 2.3.0 obtained from Thermo Fisher Scientific web site.

145

146 **Serology Test**

147 Antibody titers for IgG and IgM antibodies against SARS-CoV-2 were obtained using the
148 EDI™ Novel Coronavirus COVID-19 IgG and IgM ELISA Kits (Epitope Diagnostics, San
149 Diego, CA) following manufacturer instructions. Briefly, serum samples were diluted (1:50
150 and 1:100) and incubated in the microtiter wells of a microplate that is coated with COVID
151 recombinant full length nucleocapsid protein (SARS-CoV-2 antigen). Positive and negative
152 control calibrators were included. Results were reported as positive or negative at the
153 specific dilution (1:50 or 1:100 for IgG and 1:10 for IgM) based on the optical density
154 (OD). The cutoffs were calculated considering the average value of the absorbance of the
155 negative control (xNC). The cutoffs for IgG antibodies were calculated using the following
156 formulas: Positive cutoff = $1.1 \times (xNC + 0.18)$ and negative cutoff = $0.9 \times (xNC + 0.18)$.

157 Cutoff values < 0.284 were considered negative, > 0.284 to < 0.3476 were considered
158 borderline, and > 0.3476 were considered positive, per manufacturer instructions. The
159 cutoffs for IgM antibodies were calculated using the following formulas: Positive cutoff =
160 $1.1 \times (\text{xNC} + 0.10)$ and negative cutoff = $0.9 \times (\text{xNC} + 0.10)$. Cutoff values < 0.218 were
161 considered negative, > 0.218 to < 0.265 were considered borderline, and > 0.265 were
162 considered positive, per manufacturer instructions.

163

164 **Statistical Analysis**

165 Frequencies and percentages are used for categorical data, and medians and interquartile
166 ranges for continuous variables. GraphPad Prism 7.0 was used for plotting graphs and
167 statistical analysis.

168

169 **Results**

170 **Patient characteristics**

171 We report eight patients (2 female, 6 male) critically ill with a confirmed diagnosis of
172 COVID-19 that were admitted to our institution from March 10, 2020 to May 21, 2020 and
173 received CP therapy. The median age was 57 (IQR, 48-69), the median time from onset of
174 symptoms to admission was 6 days (IQR, 3.00-8.75) and the median length of stay 22.5
175 days (IQR, 18.25-29.00) (**Table 1**). The most common comorbidities present were
176 overweight/obesity (87.5%), hypertension (50%), diabetes mellitus (25%) and smoking
177 (12.5%). The most common symptoms on admission were fever (100%) and dyspnea
178 (100%), followed by cough (87.5%) and myalgia/arthritis (75%). Seven out of eight

179 patients (87.5%) received chloroquine/hydroxychloroquine, lopinavir/ritonavir, and
 180 azithromycin. Six patients (75%) received ceftaroline and 3 patients (37.5%) tocilizumab.

181

182 **Table 1. Baseline clinical and demographic characteristics.**

183

Variable	<i>n</i> = 8
Age , median (IQR), yr	57 (48-69)
> 60, No. (%)	3 (37.5)
Female , No. (%)	2 (25)
Male , No. (%)	6 (75)
Time from onset to admission , median (IQR), days	6 (3-8.75)
Length of stay , median (IQR), days	22.5 (18.25-29)
Comorbidities , No. (%)	
Smoking	1 (12.5)
Hypertension	4 (50)
Diabetes	2 (25)
Overweight/obesity	7 (87.5)
Symptoms at admission , No. (%)	
Fever	8 (100)
Nasal congestion	1 (12.5)
Headache	2 (25)
Cough	7 (87.5)
Sputum	2 (25)
Odynophagia	3 (37.5)
Dyspnea	8 (100)
Myalgia/arthralgia	6 (75)
Chills/diaphoresis	4 (50)
Clinical parameters , median (IQR)	
Heart rate , bpm	100 (78.75-135)
Respiratory rate , rpm	25 (17.75-31.5)
Temperature , °C	37.85 (36.8-38.22)
SOFA , pts	2 (2-4.25)
QSOFA , pts	0.5 (0-1)
CURB65 , pts	1 (0.25-1.75)
PSI , pts	78.5 (61.5-85.75)
Treatment , No. (%)	7 (87.5)
Chloroquine/Hydroxychloroquine	7 (87.5)
Lopinavir/Ritonavir	7 (87.5)
Azithromycin	6 (75)
Ceftaroline	3 (37.5)

200

201

202

203 Five patients (62.5%) were under mechanical ventilation and three patients (37.5%) high-
204 flow oxygen therapy (**Table 2**). The median duration of ventilatory/oxygen therapy was
205 12.5 days (IQR, 7.50-14.75). Under ventilatory/oxygen support, the median SaO₂ was 90%
206 (IQR, 82.50-94.25), the median FiO₂ was 40% (IQR, 36.25-47.50) and the median
207 SaO₂/FiO₂ ratio was 2.25 (IQR, 1.67-2.61). No adverse effects were observed.

208

209 **Table 2. Baseline laboratory and respiratory parameters.**

210

Laboratory parameters, median (IQR)	<i>n</i> = 8
Hemoglobin, g/dL	13.85 (12.7-14.75)
Platelets, x 10³ /μL	204.5 (193-234)
Glucose, mg/dL	121 (86.5-142.75)
AST, U/L	40.5 (23.5-45)
ALT, U/L	45 (25.25-61.5)
Total bilirubin, mg/dL	0.60 (0.3-0.9)
Creatinine, mg/dL	0.9 (0.73-1.08)
BUN, mg/dL	12.35 (8.75-16.45)
Sodium, mEq/L	136.5 (134.25-140.5)
Potassium, mEq/L	4.25 (3.8-4.65)
Chloride, mEq/L	101.5 (98-107.07)
Respiratory parameters	
Mechanical ventilation, No. (%)	5 (62.5)
High flow oxygen therapy, No. (%)	3 (37.5)
Duration of ventilatory/oxygen therapy, median (IQR), days	12.5 (7.50-14.75)
SaO₂, median (IQR), %	90 (82.5-94.25)
FiO₂, median (IQR), %	40 (36.25-47.5)
SAFI, median (IQR)	2.25 (1.67-2.61)

223

224

225 **Laboratory parameters**

226 Seven out of eight patients (87.5%) showed lymphocytopenia on admission and showed a
227 slight improvement after CP therapy (median, $0.75 \times 10^3 /\mu\text{L}$ vs. $0.83 \times 10^3 /\mu\text{L}$) (**Fig 1**).
228 Three patients (37.5%) were found with leukocytosis on admission, and the leukocyte count
229 increased after CP therapy (median, $7.40 \times 10^3 /\mu\text{L}$ vs. $11.70 \times 10^3 /\mu\text{L}$). Other laboratory
230 parameters used as markers of inflammation were found with mixed results. We observed a
231 reduction of C-reactive protein (CRP) (median, 22.80 mg/dL vs. 1.63 mg/dL), and of
232 procalcitonin (median, 0.27 ng/mL vs. 0.13 ng/mL) after CP therapy. On the other hand, an
233 increase of IL-6 (median, 16.00 pg/mL vs. 65.79 pg/mL) and ferritin (median, 421.0 ng/mL
234 vs. 919.0 ng/mL) was observed after CP therapy.

235

236 **Fig 1. Markers of inflammation before and after CP therapy.**

237 Dynamic changes of inflammation markers before and after CP therapy in all patients.

238 Dotted horizontal lines represent reference value ranges.

239

240 A reduction of injury markers was observed (**Fig 2**): High-Sensitivity Cardiac Troponin I
241 (hs-cTnI) (median, 8.20 ng/L vs. 1.50 ng/L), Brain Natriuretic Peptide (BNP) (median,
242 50.50 pg/mL vs. 14.20 pg/mL) and Lactate Dehydrogenase (median, 368.0 U/L vs. 325.0
243 U/L) were lower after CP therapy. An increase of D-dimer was observed after CP therapy
244 (median, 393 ng/mL vs. 900 ng/mL).

245

246 **Fig 2. Markers of cellular injury before and after CP therapy.**

247 Dynamic changes of cellular injury markers before and after CP therapy in all patients.

248 Dotted horizontal lines represent reference value ranges.

249

250 **Pulmonary infiltrates**

251 A mild reduction of pulmonary infiltrates severity score by chest X-ray was observed
252 (median, 6 vs 5). Representative chest x-ray images for two patients, along with the
253 severity score, before and after CP therapy, are shown (**Fig 3**).

254

255 **Fig 3. Severity of chest x-ray pulmonary infiltrates before and after CP therapy.**

256 Dynamic changes of lung infiltrates on chest X-ray before and after CP therapy. **A)**

257 Changes in lung infiltrates as assessed by a severity score, in all patients. **B)** Representative
258 images of the chest X-ray of two patients before and after CP therapy.

259

260 **Viral load**

261 On a separate group of 44 patients (23 with mild/asymptomatic course, 21 with severe
262 course) we observed an association between viral load and disease severity (**Fig 4A**).

263 Patients with severe COVID-19, defined as requiring hospitalization, showed a higher viral
264 load (log, median [IQR], 0.90 [0.30-1.34] vs. 1.67 [0.74-2.22], $p < 0.05$). This led us to
265 question whether viral load could be associated with clinical course after CP therapy on
266 COVID-19 patients with severe illness. A reduction of viral load was observed in the group
267 of eight hospitalized patients with severe COVID-19 after CP therapy (log, median [IQR],
268 1.2 [0.70-2.20] vs. 0.25 [0.00-1.78]) (**Fig 4B**).

269

270 **Fig 4. Viral load and COVID-19 disease severity.**

271 **A)** Viral load in asymptomatic/mild cases vs. hospitalized patients with severe illness, in a
272 different study group. **B)** Dynamic changes of viral load determined before and after CP
273 therapy for all the original group patients.

274

275 **Discussion**

276 The major findings of this paper are: first, it was safe to administer CP to COVID-19
277 patients with impending respiratory failure. Second, inflammatory and cellular injury
278 markers showed a decreasing tendency following CP administration. Third, significant
279 improvements were observed in pulmonary infiltrates. Fourth, sequential analysis of viral
280 load in respiratory samples showed a progressive reduction over-time. And finally, all
281 patients were discharged home. Taken together, these observations support the hypothesis
282 of the effectiveness of CP for COVID-19 patients with impending respiratory failure. To
283 our knowledge, this is the first reported experience in Mexico of CP use for patients with
284 COVID-19 with impending respiratory failure.

285 Experience with CP therapy is vast, as it has been utilized since the early twentieth
286 century. During the 1918 influenza virus pandemic, CP therapy was implemented and
287 evidence suggests it had an impact reducing mortality (10,11). Moreover, the use of CP has
288 been evaluated for the treatment of several viral illnesses, such as Influenza A (H1N1),
289 SARS, MERS and Ebola (12–16), and has been associated to reductions in mortality. For
290 newly emerging viral mediated diseases, such as COVID-19, with no objective treatments,
291 it provides at least a reasonable and testable approach. Moreover, it has been considered a

292 lower cost alternative (4), and its use could be advantageous for developing countries,
293 provided its efficacy is demonstrated by randomized controlled trials.

294 The primary hypothesis of the mechanism of action of CP therapy for COVID-19
295 focuses on the fact that recovered individuals have developed antibodies that can neutralize
296 viral activity and therefore, accelerate the recovery process (5,10,17–19). But this topic has
297 been revisited recently (5). The mechanisms of action of CP are, probably, more extensive
298 and therefore, best described as those that may result from direct antiviral activity and those
299 that result from immunomodulation (5).

300 The antiviral activity of CP, in general, is likely the result of the presence of
301 neutralizing antibodies (NAbs) (10,18,20,21), and to our knowledge this is yet to be
302 confirmed for COVID-19 (6). It is possible that the number of neutralizing antibodies
303 produced during the infection, or administered with therapeutic intent, determines to some
304 extent the disease severity and clinical outcomes.

305 But NAbs represent only a subset of all antibodies produced against the virus. The
306 immunomodulatory effects of CP may result, in part, from antibodies that block the effect
307 of autoantibodies, proinflammatory cytokines and complement activation (5). In the context
308 of COVID-19, possible immunomodulatory effects of CP could be equally important. In
309 this sense, COVID-19 infection is associated with a profound inflammatory response
310 beyond the injury that results from viral cellular damage (22–27).

311 Various strategies directed at modulating the immune response are currently being
312 used off-label or are being studied in clinical trials, but evidence in favor or against their
313 use for COVID-19 is still insufficient (28). The most representative therapies that target
314 immunomodulation are interleukin-1 (IL-1) and interleukin-6 (IL-6) inhibitors, others
315 include interferons alfa and beta, and Janus Kinase (JAK) inhibitors. For example,

316 Tocilizumab, an IL-6 receptor antagonist already FDA approved for rheumatoid arthritis
317 among other indications, has shown promising results for the treatment of COVID-19 in
318 preliminary reports (29–31).

319 In a recent, multicenter, randomized clinical trial, CP therapy for patients with
320 severe COVID-19 was associated with antiviral activity, shown as a higher rate of negative
321 SARS-CoV-2 PCR up to 72 hours later (6). The findings of our paper are consistent with
322 this observation (**Figure 4B**). To understand this further, we compared viral loads among
323 asymptomatic SARS-CoV-2 PCR positive patients vs. COVID-19 hospitalized patients
324 (**Figure 4A**). We found a significant difference among said groups. Hospitalized patients
325 had higher viral loads than asymptomatic ambulatory patients. This observation suggests,
326 that at least at some point in the disease process, viral loads are associated with disease
327 severity (32). Moreover, we observed a decreasing tendency for inflammatory markers and
328 pulmonary infiltrates severity after CP therapy, consistent with previous reports (8).

329 There are limitations to our present study. Patients were receiving standard care,
330 which could interact with the course of illness or with CP therapy. Neutralizing antibodies
331 were not determined. However, our preliminary results support the completion of
332 randomized larger trials.

333 In summary, the present study supports the observations of others and reaffirms the
334 importance of conducting prospective clinical studies aimed to define not only the best
335 timing and cohort of patients in which CP should be used, but also to improve our
336 understanding of the mechanisms of action.

337

338 **Abbreviations**

339 **COVID-19:** Coronavirus Disease 2019

340 **BNP:** Brain Natriuretic Peptide

341 **CP:** Convalescent Plasma

342 **hs-cTnI:** High-sensitivity Cardiac Troponin I

343 **IL-1:** Interleukin-1

344 **IL-6:** Interleukin-6

345 **JAK:** Janus Kinase

346 **LDH:** Lactate Dehydrogenase

347 **NAbs:** Neutralizing antibodies

348 **RT-PCR:** Reverse transcription polymerase chain reaction

349 **SARS-CoV-2:** Severe acute respiratory syndrome coronavirus 2

350 **References**







- 351 1. Roser M, Ritchie H, Ortiz-Ospina E, Hasell J. Coronavirus Pandemic (COVID-19)
352 [Internet]. Our World in Data. 2020 [cited 2020 Jun 9]. Available from:
353 <https://ourworldindata.org/coronavirus>
- 354 2. Secretaría de Salud. Datos Abiertos - Dirección General de Epidemiología [Internet].
355 gob.mx. [cited 2020 Jun 9]. Available from:
356 <http://www.gob.mx/salud/documentos/datos-abiertos-152127>
- 357 3. OECD. Health equipment - Hospital beds - OECD Data [Internet]. [cited 2020 Jun 9].
358 Available from: <http://data.oecd.org/healtheq/hospital-beds.htm>
- 359 4. World Health Organization. Use of convalescent whole blood or plasma collected from
360 patients recovered from Ebola virus disease. WHO [Internet]. [cited 2020 Jun 9];
361 Available from: [https://www.who.int/csr/resources/publications/ebola/convalescent-](https://www.who.int/csr/resources/publications/ebola/convalescent-treatment/en/)
362 [treatment/en/](https://www.who.int/csr/resources/publications/ebola/convalescent-treatment/en/)
- 363 5. Rojas M, Rodríguez Y, Monsalve DM, Acosta-Ampudia Y, Camacho B, Gallo JE, et
364 al. Convalescent plasma in Covid-19: Possible mechanisms of action. *Autoimmun Rev.*
365 2020 Jul;19(7):102554.
- 366 6. Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, et al. Effect of Convalescent Plasma
367 Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening
368 COVID-19: A Randomized Clinical Trial. *JAMA.* 2020 Jun 3;





- 369 7. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 Critically Ill
370 Patients With COVID-19 With Convalescent Plasma. *JAMA*. 2020 Mar 27;
- 371 8. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma
372 therapy in severe COVID-19 patients. *Proc Natl Acad Sci USA*. 2020 Apr
373 28;117(17):9490.
- 374 9. Wong HYF, Lam HYS, Fong AH-T, Leung ST, Chin TW-Y, Lo CSY, et al. Frequency
375 and Distribution of Chest Radiographic Findings in COVID-19 Positive
376 Patients. *Radiology*. 2020 Mar 27;201160.
- 377 10. Casadevall A, Pirofski L. The convalescent sera option for containing COVID-19. *J*
378 *Clin Invest*. 2020 Apr 1;130(4):1545–8.
- 379 11. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood
380 products for Spanish influenza pneumonia: a future H5N1 treatment? *Ann Intern Med*.
381 2006 Oct 17;145(8):599–609.
- 382 12. Cheng Y, Wong R, Soo YOY, Wong WS, Lee CK, Ng MHL, et al. Use of convalescent
383 plasma therapy in SARS patients in Hong Kong. *Eur J Clin Microbiol Infect Dis*. 2005
384 Jan 1;24(1):44–6.
- 385 13. Yeh K-M, Chiueh T-S, Siu LK, Lin J-C, Chan PKS, Peng M-Y, et al. Experience of
386 using convalescent plasma for severe acute respiratory syndrome among healthcare
387 workers in a Taiwan hospital. *J Antimicrob Chemother*. 2005 Nov 1;56(5):919–22.
- 388 14. Arabi YM, Hajeer AH, Luke T, Raviprakash K, Balkhy H, Johani S, et al. Feasibility of
389 Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia -



- 390 Volume 22, Number 9—September 2016 - Emerging Infectious Diseases journal -
391 CDC. [cited 2020 Jun 10]; Available from: [https://wwwnc.cdc.gov/eid/article/22/9/15-](https://wwwnc.cdc.gov/eid/article/22/9/15-1164_article)
392 1164_article
- 393 15. Hung IF, To KK, Lee C-K, Lee K-L, Chan K, Yan W-W, et al. Convalescent plasma
394 treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009
395 virus infection. *Clin Infect Dis*. 2011 Feb 15;52(4):447–56.
- 396 16. Sahr F, Ansumana R, Massaquoi TA, Idriss BR, Sesay FR, Lamin JM, et al. Evaluation
397 of convalescent whole blood for treating Ebola Virus Disease in Freetown, Sierra
398 Leone. *J Infect*. 2017;74(3):302–9.
- 399 17. Bloch EM, Shoham S, Casadevall A, Sachais BS, Shaz B, Winters JL, et al.
400 Deployment of convalescent plasma for the prevention and treatment of COVID-19. *J*
401 *Clin Invest*. 2020 01;130(6):2757–65.
- 402 18. Rajendran K, Krishnasamy N, Rangarajan J, Rathinam J, Natarajan M, Ramachandran
403 A. Convalescent plasma transfusion for the treatment of COVID-19: Systematic
404 review. *J Med Virol*. 2020 May 1;
- 405 19. Wu F, Wang A, Liu M, Wang Q, Chen J, Xia S, et al. Neutralizing antibody responses
406 to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications.
407 *medRxiv*. 2020 Apr 20;2020.03.30.20047365.
- 408 20. Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw F-M, Lim WS, et al.
409 The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the

- 410 Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic
411 Review and Exploratory Meta-analysis. *J Infect Dis.* 2015 Jan 1;211(1):80–90.
- 412 21. Robbins JB, Schneerson R, Szu SC. Perspective: hypothesis: serum IgG antibody is
413 sufficient to confer protection against infectious diseases by inactivating the inoculum.
414 *J Infect Dis.* 1995 Jun;171(6):1387–98.
- 415 22. Valk SJ, Piechotta V, Chai KL, Doree C, Monsef I, Wood EM, et al. Convalescent
416 plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
417 *Cochrane Database Syst Rev.* 2020 14;5:CD013600.
- 418 23. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of
419 COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir Med.*
420 2020;8(4):420–2.
- 421 24. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients
422 infected with 2019 novel coronavirus in Wuhan, China. *Lancet.* 2020
423 15;395(10223):497–506.
- 424 25. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-
425 19: consider cytokine storm syndromes and immunosuppression. *Lancet.* 2020
426 28;395(10229):1033–4.
- 427 26. Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical Features of 69 Cases with
428 Coronavirus Disease 2019 in Wuhan, China. *Clin Infect Dis.* 2020 Mar 16;


- 429 27. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for
430 mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort
431 study. *Lancet*. 2020 28;395(10229):1054–62.
- 432 28. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19)
433 Treatment Guidelines. National Institutes of Health [Internet]. [cited 2020 Jun 15];
434 Available from: <https://www.covid19treatmentguidelines.nih.gov/>
- 435 29. Tocilizumab improves significantly clinical outcomes of patients with moderate or
436 severe COVID-19 pneumonia [Internet]. [cited 2020 Jun 17]. Available from:
437 [https://www.aphp.fr/contenu/tocilizumab-improves-significantly-clinical-outcomes-](https://www.aphp.fr/contenu/tocilizumab-improves-significantly-clinical-outcomes-patients-moderate-or-severe-covid-19)
438 [patients-moderate-or-severe-covid-19](https://www.aphp.fr/contenu/tocilizumab-improves-significantly-clinical-outcomes-patients-moderate-or-severe-covid-19)
- 439 30. Sciascia S, Aprà F, Baffa A, Baldovino S, Boaro D, Boero R, et al. Pilot prospective
440 open, single-arm multicentre study on off-label use of tocilizumab in patients with
441 severe COVID-19. *Clin Exp Rheumatol*. 2020 Jun;38(3):529–32.
- 442 31. Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe
443 COVID-19 patients with tocilizumab. *Proc Natl Acad Sci USA*. 2020
444 19;117(20):10970–5.
- 445 32. Zheng S, Fan J, Yu F, Feng B, Lou B, Zou Q, et al. Viral load dynamics and disease
446 severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-
447 March 2020: retrospective cohort study. *BMJ* [Internet]. 2020 Apr 21 [cited 2020 Jun
448 17];369. Available from: <https://www.bmj.com/content/369/bmj.m1443>
- 449

A**Leukocytes****B****Lymphocytes****C****C-Reactive Protein****D****Procalcitonin****E****IL-6****F****Ferritin**





A Viral Load and Disease Severity



B Viral Load

